Skip to main content

Table 2 Comparisons of HDL-cholesterol levels in the three antipsychotic groups with stratification by BMI for inpatients

From: High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey

  Olanzapine Risperidone Aripiprazole p-value Post-hoc (p-value)
HDL-cholesterol BMI < 18.5 mg/dL 62.0 ± 20.5 (34) 58.6 ± 15.8 (55) 62.6 ± 21.6 (28) 0.490  
18.5 ≤ BMI < 25 mg/dL 54.1 ± 21.5 (137) 55.0 ± 16.2 (196) 58.2 ± 15.8 (68) 0.282  
BMI ≥ 25 mg/dL 43.8 ± 12.3 (47) 49.7 ± 15.0 (84) 54.7 ± 16.8 (25) 0.019 Olanzapine < Aripiprazole (0.023)
  1. Data are shown as the mean ± SD (number of subjects)
  2. Analyses of covariance among the three antipsychotics were performed for HDL-cholesterol with age, diastolic blood pressure, chlorpromazine-equivalent dosage and waist circumference as confounding variables
  3. Post-hoc analyses were performed by the Bonferroni method
  4. HDL high-density lipoprotein, BMI body mass index